telotristat etiprate · Tersera · NDA 208794
Xermelo
Earliest generic entry, as listed
28 Feb 2031
Blocked by patent: US 7709493.
Listed patents · 5 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 7709493 | substance, use U-1979 | 28 Feb 2031 |
| US 8193204 | substance | 27 Feb 2031 |
| US 8653094 | use U-1979 | 19 Dec 2028 |
| US 7553840 | substance | 11 Dec 2027 |
| US 7968559 | use U-1979 | 11 Dec 2027 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 208794 · 001 · RLD | tablet, oral | EQ 250MG BASE | 28 Feb 2031 |